

Massimo Stefani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4545314/publications.pdf>

Version: 2024-02-01

139
papers

13,791
citations

34493

54
h-index

23841

115
g-index

143
all docs

143
docs citations

143
times ranked

13962
citing authors

#	ARTICLE	IF	CITATIONS
1	Xenohormesis underlies the anti-aging and healthy properties of olive polyphenols. Mechanisms of Ageing and Development, 2022, 202, 111620.	2.2	10
2	The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis. Pharmaceuticals, 2022, 15, 277.	1.7	3
3	Natural Compound from Olive Oil Inhibits S100A9 Amyloid Formation and Cytotoxicity: Implications for Preventing Alzheimer's Disease. ACS Chemical Neuroscience, 2021, 12, 1905-1918.	1.7	18
4	Olive Polyphenols: Antioxidant and Anti-Inflammatory Properties. Antioxidants, 2021, 10, 1044.	2.2	92
5	Structural Features and Toxicity of β -Synuclein Oligomers Grown in the Presence of DOPAC. International Journal of Molecular Sciences, 2021, 22, 6008.	1.8	8
6	EVOO Polyphenols Relieve Synergistically Autophagy Dysregulation in a Cellular Model of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 7225.	1.8	13
7	Insight into the molecular mechanism underlying the inhibition of β -synuclein aggregation by hydroxytyrosol. Biochemical Pharmacology, 2020, 173, 113722.	2.0	25
8	Allium roseum L. extract inhibits amyloid beta aggregation and toxicity involved in Alzheimer's disease. PLoS ONE, 2020, 15, e0223815.	1.1	11
9	The Amphipathic GM1 Molecule Stabilizes Amyloid Aggregates, Preventing their Cytotoxicity. Biophysical Journal, 2020, 119, 326-336.	0.2	7
10	Healthy Effects of Plant Polyphenols: Molecular Mechanisms. International Journal of Molecular Sciences, 2020, 21, 1250.	1.8	265
11	Healthspan Maintenance and Prevention of Parkinson's-like Phenotypes with Hydroxytyrosol and Oleuropein Aglycone in C. elegans. International Journal of Molecular Sciences, 2020, 21, 2588.	1.8	110
12	Oleuropein aglycone and hydroxytyrosol interfere differently with toxic A β ₁₋₄₂ aggregation. Food and Chemical Toxicology, 2019, 129, 1-12.	1.8	46
13	1,2,4-trihydroxynaphthalene-2-O- β -D-glucopyranoside: A new powerful antioxidant and inhibitor of A β ₄₂ aggregation isolated from the leaves of Lawsonia inermis. Natural Product Research, 2019, 33, 1406-1414.	1.0	11
14	1,2,4-trihydroxynaphthalene-2-O- β -D-glucopyranoside delays amyloid A β ₄₂ aggregation and reduces amyloid cytotoxicity. BioFactors, 2018, 44, 272-280.	2.8	2
15	A new purified Lawsoniaside remodels amyloid- β ₄₂ fibrillation into a less toxic and non-amyloidogenic pathway. International Journal of Biological Macromolecules, 2018, 114, 830-835.	3.6	1
16	Diet Supplementation with Hydroxytyrosol Ameliorates Brain Pathology and Restores Cognitive Functions in a Mouse Model of Amyloid- β Deposition. Journal of Alzheimer's Disease, 2018, 63, 1161-1172.	1.2	39
17	Oleuropein aglycone: A polyphenol with different targets against amyloid toxicity. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 1432-1442.	1.1	30
18	Toxic HypF-N Oligomers Selectively Bind the Plasma Membrane to Impair Cell Adhesion Capability. Biophysical Journal, 2018, 114, 1357-1367.	0.2	8

#	ARTICLE	IF	CITATIONS
19	Screening for amyloid- β^2 aggregation inhibitor and neuronal toxicity of eight Tunisian medicinal plants. <i>Industrial Crops and Products</i> , 2018, 111, 823-833.	2.5	14
20	Oleuropein aglycone stabilizes the monomeric β -synuclein and favours the growth of non-toxic aggregates. <i>Scientific Reports</i> , 2018, 8, 8337.	1.6	54
21	Oleuropein Aglycone Protects against MAO-A-Induced Autophagy Impairment and Cardiomyocyte Death through Activation of TFEB. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-13.	1.9	35
22	A FTIR microspectroscopy study of the structural and biochemical perturbations induced by natively folded and aggregated transthyretin in HL-1 cardiomyocytes. <i>Scientific Reports</i> , 2018, 8, 12508.	1.6	31
23	Oleuropein aglycone and polyphenols from olive mill waste water ameliorate cognitive deficits and neuropathology. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 54-62.	1.1	70
24	A specific nanobody prevents amyloidogenesis of D76N β 2-microglobulin in vitro and modifies its tissue distribution in vivo. <i>Scientific Reports</i> , 2017, 7, 46711.	1.6	18
25	Soluble Oligomers Require a Ganglioside to Trigger Neuronal Calcium Overload. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 923-938.	1.2	41
26	Olive polyphenols: new promising agents to combat aging-associated neurodegeneration. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 345-358.	1.4	99
27	Nutraceutical Properties of Olive Oil Polyphenols. An Itinerary from Cultured Cells through Animal Models to Humans. <i>International Journal of Molecular Sciences</i> , 2016, 17, 843.	1.8	222
28	The Polyphenol Oleuropein Aglycone Modulates the PARP1-SIRT1 Interplay: An In Vitro and In Vivo Study. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 737-750.	1.2	36
29	Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes. <i>Biophysical Journal</i> , 2016, 111, 2024-2038.	0.2	19
30	Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases. <i>Scientific Reports</i> , 2016, 6, 32721.	1.6	107
31	Single molecule experiments emphasize GM1 as a key player of the different cytotoxicity of structurally distinct $A\beta^{1-42}$ oligomers. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2016, 1858, 386-392.	1.4	22
32	Molecular insights into cell toxicity of a novel familial amyloidogenic variant of β 2-microglobulin. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1443-1456.	1.6	23
33	The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies. <i>Journal of Nutritional Biochemistry</i> , 2016, 30, 153-166.	1.9	39
34	Interaction of toxic and non-toxic HypF-N oligomers with lipid bilayers investigated at high resolution with atomic force microscopy. <i>Oncotarget</i> , 2016, 7, 44991-45004.	0.8	23
35	Nutraceuticals and amyloid neurodegenerative diseases: a focus on natural phenols. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 41-52.	1.4	56
36	Oleuropein Aglycone: A Possible Drug against Degenerative Conditions. In Vivo Evidence of its Effectiveness against Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 679-688.	1.2	59

#	ARTICLE	IF	CITATIONS
37	Oleuropein aglycone protects against pyroglutamylated-3 amyloid- β toxicity: biochemical, epigenetic and functional correlates. <i>Neurobiology of Aging</i> , 2015, 36, 648-663.	1.5	91
38	Oleuropein aglycone induces autophagy <i>via</i> the AMPK/mTOR signalling pathway: a mechanistic insight. <i>Oncotarget</i> , 2015, 6, 35344-35357.	0.8	108
39	Employing Alzheimer Disease Animal Models for Translational Research: Focus on Dietary Components. <i>Neurodegenerative Diseases</i> , 2014, 13, 131-134.	0.8	25
40	Amyloid Aggregation: Role of Biological Membranes and the Aggregate- β Membrane System. <i>Journal of Physical Chemistry Letters</i> , 2014, 5, 517-527.	2.1	88
41	Oleuropein aglycone counteracts $A\beta^{242}$ toxicity in the rat brain. <i>Neuroscience Letters</i> , 2014, 558, 67-72.	1.0	66
42	Beneficial properties of natural phenols: Highlight on protection against pathological conditions associated with amyloid aggregation. <i>BioFactors</i> , 2014, 40, 482-493.	2.6	83
43	Mild exposure of RIN-5F β -cells to human islet amyloid polypeptide aggregates upregulates antioxidant enzymes via NADPH oxidase-RAGE: An hormetic stimulus. <i>Redox Biology</i> , 2014, 2, 114-122.	3.9	15
44	Protein Folding and Aggregation into Amyloid: The Interference by Natural Phenolic Compounds. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12411-12457.	1.8	180
45	Different ataxin-3 amyloid aggregates induce intracellular Ca^{2+} deregulation by different mechanisms in cerebellar granule cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 3155-3165.	1.9	22
46	The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity. <i>Biophysical Chemistry</i> , 2013, 182, 30-43.	1.5	96
47	Oleuropein Aglycone Protects Transgenic <i>C. elegans</i> Strains Expressing $A\beta^{242}$ by Reducing Plaque Load and Motor Deficit. <i>PLoS ONE</i> , 2013, 8, e58893.	1.1	116
48	The Polyphenol Oleuropein Aglycone Protects TgCRND8 Mice against $A\beta$ Plaque Pathology. <i>PLoS ONE</i> , 2013, 8, e71702.	1.1	202
49	Membrane lipid composition and its physicochemical properties define cell vulnerability to aberrant protein oligomers. <i>Journal of Cell Science</i> , 2012, 125, 2416-27.	1.2	75
50	Toxic effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1. <i>FASEB Journal</i> , 2012, 26, 818-831.	0.2	118
51	Structural features and cytotoxicity of amyloid oligomers: Implications in Alzheimer's disease and other diseases with amyloid deposits. <i>Progress in Neurobiology</i> , 2012, 99, 226-245.	2.8	154
52	Interactions of lysozyme with phospholipid vesicles: effects of vesicle biophysical features on protein misfolding and aggregation. <i>Soft Matter</i> , 2012, 8, 9115.	1.2	28
53	Lysozyme interaction with negatively charged lipid bilayers: protein aggregation and membrane fusion. <i>Soft Matter</i> , 2012, 8, 4524.	1.2	32
54	Neuronal Differentiation of Human Mesenchymal Stromal Cells Increases their Resistance to $A\beta^{242}$ Aggregate Toxicity. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 651-664.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Does azurin bind to the transactivation domain of p53? A Trp phosphorescence study. <i>Biophysical Chemistry</i> , 2011, 159, 287-293.	1.5	9
56	Aβ(1-42) Aggregates into Non-Toxic Amyloid Assemblies in the Presence of the Natural Polyphenol Oleuropein Aglycon. <i>Current Alzheimer Research</i> , 2011, 8, 841-852.	0.7	113
57	Effect of Tetracyclines on the Dynamics of Formation and Deconstruction of β 2-Microglobulin Amyloid Fibrils. <i>Journal of Biological Chemistry</i> , 2011, 286, 2121-2131.	1.6	87
58	Structural Polymorphism of Amyloid Oligomers and Fibrils Underlies Different Fibrillization Pathways: Immunogenicity and Cytotoxicity. <i>Current Protein and Peptide Science</i> , 2010, 11, 343-354.	0.7	33
59	Oleuropein aglycon prevents cytotoxic amyloid aggregation of human amylin β . <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 726-735.	1.9	107
60	Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. <i>FEBS Journal</i> , 2010, 277, 4602-4613.	2.2	164
61	A causative link between the structure of aberrant protein oligomers and their toxicity. <i>Nature Chemical Biology</i> , 2010, 6, 140-147.	3.9	499
62	Embryonic stem and haematopoietic progenitor cells resist to $A\beta$ oligomer toxicity and maintain the differentiation potency in culture. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2010, 17, 137-145.	1.4	3
63	Protein Aggregation Diseases: Toxicity of Soluble Prefibrillar Aggregates and Their Clinical Significance. <i>Methods in Molecular Biology</i> , 2010, 648, 25-41.	0.4	21
64	Cholesterol in Alzheimers Disease: Unresolved Questions. <i>Current Alzheimer Research</i> , 2009, 6, 15-29.	0.7	123
65	Proteomic analysis of cells exposed to prefibrillar aggregates of HypF-N. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2009, 1794, 1243-1250.	1.1	3
66	A protective role for lipid raft cholesterol against amyloid-induced membrane damage in human neuroblastoma cells. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2009, 1788, 2204-2216.	1.4	66
67	Synthetic Lipid Vesicles Recruit Native-Like Aggregates and Affect the Aggregation Process of the Prion Ure2p: Insights on Vesicle Permeabilization and Charge Selectivity. <i>Biophysical Journal</i> , 2009, 96, 3319-3330.	0.2	16
68	Differentiation Increases the Resistance of Neuronal Cells to Amyloid Toxicity. <i>Neurochemical Research</i> , 2008, 33, 2516-2531.	1.6	31
69	Replicating neuroblastoma cells in different cell cycle phases display different vulnerability to amyloid toxicity. <i>Journal of Molecular Medicine</i> , 2008, 86, 197-209.	1.7	23
70	Biological function in a non-native partially folded state of a protein. <i>EMBO Journal</i> , 2008, 27, 1525-35.	3.5	32
71	Protein Folding and Misfolding on Surfaces. <i>International Journal of Molecular Sciences</i> , 2008, 9, 2515-2542.	1.8	67
72	The (1-63) Region of the p53 Transactivation Domain Aggregates In Vitro into Cytotoxic Amyloid Assemblies. <i>Biophysical Journal</i> , 2008, 94, 3635-3646.	0.2	50

#	ARTICLE	IF	CITATIONS
73	Nonspecific Interaction of Prefibrillar Amyloid Aggregates with Glutamatergic Receptors Results in Ca ²⁺ Increase in Primary Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 29950-29960.	1.6	46
74	Å2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 1176-1181.	0.4	31
75	Generic Cell Dysfunction in Neurodegenerative Disorders: Role of Surfaces in Early Protein Misfolding, Aggregation, and Aggregate Cytotoxicity. <i>Neuroscientist</i> , 2007, 13, 519-531.	2.6	69
76	The intrachain disulfide bridge is responsible of the unusual stability properties of novel acylphosphatase from <i>Escherichia coli</i> . <i>FEBS Letters</i> , 2006, 580, 6763-6768.	1.3	10
77	Natively Folded HypF-N and Its Early Amyloid Aggregates Interact with Phospholipid Monolayers and Destabilize Supported Phospholipid Bilayers. <i>Biophysical Journal</i> , 2006, 91, 4575-4588.	0.2	46
78	Assessing the role of aromatic residues in the amyloid aggregation of human muscle acylphosphatase. <i>Protein Science</i> , 2006, 15, 862-870.	3.1	107
79	Prefibrillar Amyloid Aggregates Could Be Generic Toxins in Higher Organisms. <i>Journal of Neuroscience</i> , 2006, 26, 8160-8167.	1.7	222
80	Differing molecular mechanisms appear to underlie early toxicity of prefibrillar HypF-N aggregates to different cell types. <i>FEBS Journal</i> , 2006, 273, 2206-2222.	2.2	15
81	The Yeast Prion Ure2p Native-like Assemblies Are Toxic to Mammalian Cells Regardless of Their Aggregation State*. <i>Journal of Biological Chemistry</i> , 2006, 281, 15337-15344.	1.6	41
82	Preliminary characterization of two different crystal forms of acylphosphatase from the hyperthermophile archaeon <i>Sulfolobus solfataricus</i> . <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2005, 61, 144-146.	0.7	3
83	Structure, conformational stability, and enzymatic properties of acylphosphatase from the hyperthermophile <i>Sulfolobus solfataricus</i> . <i>Proteins: Structure, Function and Bioinformatics</i> , 2005, 62, 64-79.	1.5	43
84	Patterns of cell death triggered in two different cell lines by HypF-N prefibrillar aggregates. <i>FASEB Journal</i> , 2005, 19, 1-23.	0.2	42
85	Investigating the Effects of Mutations on Protein Aggregation in the Cell. <i>Journal of Biological Chemistry</i> , 2005, 280, 10607-10613.	1.6	75
86	Insights into the molecular basis of the differing susceptibility of varying cell types to the toxicity of amyloid aggregates. <i>Journal of Cell Science</i> , 2005, 118, 3459-3470.	1.2	85
87	Reversal of Protein Aggregation Provides Evidence for Multiple Aggregated States. <i>Journal of Molecular Biology</i> , 2005, 346, 603-616.	2.0	86
88	Aggregation of the Acylphosphatase from <i>Sulfolobus solfataricus</i> . <i>Journal of Biological Chemistry</i> , 2004, 279, 14111-14119.	1.6	99
89	Three-dimensional structural characterization of a novel <i>Drosophila melanogaster</i> acylphosphatase. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2004, 60, 1177-1179.	2.5	18
90	Selection of antibody fragments specific for an α -helix region of acylphosphatase. <i>Journal of Molecular Recognition</i> , 2004, 17, 62-66.	1.1	3

#	ARTICLE	IF	CITATIONS
91	Studying the Folding Process of the Acylphosphatase from <i>Sulfolobus solfataricus</i> . A Comparative Analysis with Other Proteins from the Same Superfamily. <i>Biochemistry</i> , 2004, 43, 9116-9126.	1.2	19
92	Prefibrillar Amyloid Protein Aggregates Share Common Features of Cytotoxicity. <i>Journal of Biological Chemistry</i> , 2004, 279, 31374-31382.	1.6	346
93	Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2004, 1739, 5-25.	1.8	366
94	Monitoring the Process of HypF Fibrillization and Liposome Permeabilization by Protofibrils. <i>Journal of Molecular Biology</i> , 2004, 338, 943-957.	2.0	101
95	Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. <i>Journal of Molecular Medicine</i> , 2003, 81, 678-699.	1.7	1,444
96	Rationalization of the effects of mutations on peptide and protein aggregation rates. <i>Nature</i> , 2003, 424, 805-808.	13.7	1,013
97	Relative Influence of Hydrophobicity and Net Charge in the Aggregation of Two Homologous Proteins. <i>Biochemistry</i> , 2003, 42, 15078-15083.	1.2	115
98	Comparison of the Folding Processes of Distantly Related Proteins. Importance of Hydrophobic Content in Folding. <i>Journal of Molecular Biology</i> , 2003, 330, 577-591.	2.0	47
99	Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16419-16426.	3.3	268
100	Crystal Structure and Anion Binding in the Prokaryotic Hydrogenase Maturation Factor HypF Acylphosphatase-like Domain. <i>Journal of Molecular Biology</i> , 2002, 321, 785-796.	2.0	63
101	Crystallization and preliminary X-ray characterization of the acylphosphatase-like domain from the <i>Escherichia coli</i> hydrogenase maturation factor HypF. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2002, 58, 524-525.	2.5	6
102	Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. <i>Nature</i> , 2002, 416, 507-511.	13.7	2,322
103	Kinetic partitioning of protein folding and aggregation. <i>Nature Structural Biology</i> , 2002, 9, 137-143.	9.7	373
104	Detection of two partially structured species in the folding process of the amyloidogenic protein β 2-microglobulin. <i>Journal of Molecular Biology</i> , 2001, 307, 379-391.	2.0	115
105	Reduction of the amyloidogenicity of a protein by specific binding of ligands to the native conformation. <i>Protein Science</i> , 2001, 10, 879-886.	3.1	62
106	Folding and Aggregation Are Selectively Influenced by the Conformational Preferences of the α -Helices of Muscle Acylphosphatase. <i>Journal of Biological Chemistry</i> , 2001, 276, 37149-37154.	1.6	45
107	Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N-terminal domain. <i>Protein Science</i> , 2001, 10, 2541-2547.	3.1	47
108	Initial denaturing conditions influence the slow folding phase of acylphosphatase associated with proline isomerization. <i>Protein Science</i> , 2000, 9, 1466-1473.	3.1	5

#	ARTICLE	IF	CITATIONS
109	Stabilisation of α -helices by site-directed mutagenesis reveals the importance of secondary structure in the transition state for acylphosphatase folding. <i>Journal of Molecular Biology</i> , 2000, 300, 633-647.	2.0	53
110	Mutational analysis of acylphosphatase suggests the importance of topology and contact order in protein folding. <i>Nature Structural Biology</i> , 1999, 6, 1005-1009.	9.7	257
111	The lowMrphosphotyrosine protein phosphatase behaves differently when phosphorylated at Tyr131 or Tyr132 by Src kinase. <i>FEBS Letters</i> , 1999, 456, 73-78.	1.3	63
112	Thermodynamics and Kinetics of Folding of Common-Type Acylphosphatase: A Comparison to the Highly Homologous Muscle Isoenzyme. <i>Biochemistry</i> , 1999, 38, 2135-2142.	1.2	51
113	Sequence-specific recognition of peptide substrates by the lowMrphosphotyrosine protein phosphatase isoforms. <i>FEBS Letters</i> , 1998, 422, 213-217.	1.3	13
114	Conformational Stability of Muscle Acylphosphatase: The Role of Temperature, Denaturant Concentration, and pH. <i>Biochemistry</i> , 1998, 37, 1447-1455.	1.2	57
115	Structural characterization of the transition state for folding of muscle acylphosphatase 1 Edited by P. E. Wright. <i>Journal of Molecular Biology</i> , 1998, 283, 893-903.	2.0	54
116	Structural and Kinetic Investigations on the 15 [~] 21 and 42 [~] 45 Loops of Muscle Acylphosphatase: Evidence for Their Involvement in Enzyme Catalysis and Conformational Stabilization. <i>Biochemistry</i> , 1997, 36, 7217-7224.	1.2	14
117	Structural, catalytic, and functional properties of low Mr phosphotyrosine protein phosphatases. Evidence of a long evolutionary history. <i>International Journal of Biochemistry and Cell Biology</i> , 1997, 29, 279-292.	1.2	51
118	Structure and function of the low Mr phosphotyrosine protein phosphatases. <i>BBA - Proteins and Proteomics</i> , 1997, 1341, 137-156.	2.1	95
119	Looking for Residues Involved in the Muscle Acylphosphatase Catalytic Mechanism and Structural Stabilization: Role of Asn41, Thr42, and Thr46. <i>Biochemistry</i> , 1996, 35, 7077-7083.	1.2	48
120	C-terminal region contributes to muscle acylphosphatase three-dimensional structure stabilisation. <i>FEBS Letters</i> , 1996, 384, 172-176.	1.3	12
121	Expression, Purification, and Characterization of Acylphosphatase Muscular Isoenzyme as Fusion Protein with Glutathione S-Transferase. <i>Protein Expression and Purification</i> , 1995, 6, 799-805.	0.6	28
122	Properties of N-terminus truncated and C-terminus mutated muscle acylphosphatases. <i>FEBS Letters</i> , 1995, 362, 175-179.	1.3	11
123	Arginine-23 is involved in the catalytic site of muscle acylphosphatase. <i>BBA - Proteins and Proteomics</i> , 1994, 1208, 75-80.	2.1	31
124	The crystal structure of a low-molecular-weight phosphotyrosine protein phosphatase. <i>Nature</i> , 1994, 370, 575-578.	13.7	224
125	Equilibrium Unfolding Studies of Horse Muscle Acylphosphatase. <i>FEBS Journal</i> , 1994, 225, 811-817.	0.2	20
126	Aspartic-129 is an essential residue in the catalytic mechanism of the lowMrphosphotyrosine protein phosphatase. <i>FEBS Letters</i> , 1994, 350, 328-332.	1.3	47

#	ARTICLE	IF	CITATIONS
127	Crystallisation of a low molecular weight phosphotyrosine protein phosphatase from bovine liver. FEBS Letters, 1994, 343, 107-108.	1.3	3
128	Dephosphorylation of tyrosine phosphorylated synthetic peptides by rat liver phosphotyrosine protein phosphatase isoenzymes. FEBS Letters, 1993, 326, 131-134.	1.3	61
129	Expression and turnover of acylphosphatase (muscular isoenzyme) in L6 myoblasts during myogenesis. Archives of Biochemistry and Biophysics, 1992, 294, 261-264.	1.4	23
130	Preparation and properties of <i>des</i> -Tyr ⁹⁸ and <i>des</i> -Arg ⁹⁷ -Tyr ⁹⁸ acylphosphatase (muscular isoenzyme). International Journal of Peptide and Protein Research, 1991, 38, 278-284.	0.1	3
131	The sequence-specific assignment of the 1H-NMR spectrum of an enzyme, horse-muscle acylphosphatase. FEBS Journal, 1989, 182, 85-93.	0.2	19
132	Mobility of secondary structure units of horse-muscle acylphosphatase. Relation to antigenicity. FEBS Journal, 1989, 185, 99-103.	0.2	10
133	Guinea pig acylphosphatase: The amino acid sequence. The Protein Journal, 1988, 7, 417-426.	1.1	10
134	Duck skeletal muscle acylphosphatase: Primary structure. The Protein Journal, 1986, 5, 307-321.	1.1	12
135	Rabbit skeletal muscle acylphosphatase: The amino acid sequence of form Ra1. Archives of Biochemistry and Biophysics, 1985, 241, 418-424.	1.4	28
136	The primary structure of turkey muscle acylphosphatase. FEBS Journal, 1983, 137, 269-277.	0.2	21
137	Hydrolysis by horse muscle acylphosphatase of (Ca ²⁺ + Mg ²⁺)-ATPase phosphorylated intermediate. Archives of Biochemistry and Biophysics, 1981, 208, 37-41.	1.4	34
138	Effect of acylphosphates on Ca ²⁺ uptake by sarcoplasmic reticulum vesicles. Archives of Biochemistry and Biophysics, 1980, 200, 357-363.	1.4	12
139	PREPARATION AND SOME PROPERTIES OF A DIMERIC FORM (S ₂) OF HORSE MUSCLE ACYLPHOSPHATASE. International Journal of Peptide and Protein Research, 1979, 14, 227-233.	0.1	5